The Analyst Landscape: 7 Takes On TScan Therapeutics

Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 2 0 0 0
Last 30D 1 0 0 0 0
1M Ago 3 0 0 0 0
2M Ago 0 1 0 0 0
3M Ago 1 1 0 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.43, with a high estimate of $15.00 and a low estimate of $9.00. This upward trend is evident, with the current average reflecting a 0.81% increase from the previous average price target of $12.33.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of TScan Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Andrew Fein HC Wainwright & Co. Maintains Buy $15.00 $15.00
Justin Zelin BTIG Announces Buy $12.00 -
Andrew Fein HC Wainwright & Co. Maintains Buy $15.00 $15.00
Gil Blum Needham Maintains Buy $11.00 -
David Nierengarten Wedbush Maintains Outperform $10.00 -
Peter Lawson Barclays Raises Overweight $9.00 $7.00
Andrew Fein HC Wainwright & Co. Maintains Buy $15.00 -

Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TScan Therapeutics. This offers insight into analysts' perspectives on the current state of the company. Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of TScan Therapeutics compared to the broader market. Price Targets: Analysts predict movements in price targets, offering estimates for TScan Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into TScan Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on TScan Therapeutics analyst ratings.

If you are interested in following small-capstock newsand performance you can start by tracking it here.

Discovering TScan Therapeutics: A Closer Look

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

TScan Therapeutics's Financial Performance

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Decline in Revenue: Over the 3 months period, TScan Therapeutics faced challenges, resulting in a decline of approximately -91.68% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: TScan Therapeutics's net margin excels beyond industry benchmarks, reaching -5325.44%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): TScan Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -22.01%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): TScan Therapeutics's ROA excels beyond industry benchmarks, reaching -11.75%. This signifies efficient management of assets and strong financial health.

Debt Management: TScan Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.75, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Latest Ratings for TCRX

DateFirmActionFromTo
Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy
Aug 2021Cowen & Co.Initiates Coverage OnOutperform
Aug 2021Morgan StanleyInitiates Coverage OnOverweight

View More Analyst Ratings for TCRX

View the Latest Analyst Ratings

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.